Evaluation of P53 immunostaining in patients with cutaneous melanoma
Issued Date
2024-01-01
Resource Type
ISSN
20499434
eISSN
20499442
Scopus ID
2-s2.0-85184259098
Journal Title
Biomedical Reports
Volume
20
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biomedical Reports Vol.20 No.1 (2024)
Suggested Citation
Meevassana J., Mittrakulkij C., Toworrakul P., Saensuk W., Kamolratanakul S., Siritientong T., Ruangritchankul K., Kitkumthorn N. Evaluation of P53 immunostaining in patients with cutaneous melanoma. Biomedical Reports Vol.20 No.1 (2024). doi:10.3892/BR.2023.1696 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97195
Title
Evaluation of P53 immunostaining in patients with cutaneous melanoma
Corresponding Author(s)
Other Contributor(s)
Abstract
P53 is a tumor suppressor gene that is mutated in numerous types of cancer. The aim of the present study was to determine the frequency of this mutation in cutaneous melanomas and to conduct clinicopathological characteristics and clinical outcome association analyses with the P53 mutation. P53 immunohistochemical staining was used as a surrogate marker for P53 mutation analysis to assess P53 status. In the present study, 50 pathological samples of cutaneous melanoma from 2012 to 2018 at Chulalongkorn University (Bangkok, Thailand), were subjected to anti-P53 immunohistochemistry, followed by an examination of the association between P53 statuses and clinical and pathological characteristics, along with clinical outcomes. A positive staining for anti-P53 anti-body was detected in 30% of patients (15/50) with cutaneous melanomas. Positivity was significantly associated with female sex, nodular histological subtype and Breslow level 4. Cox regression analysis revealed that an age >65.5 years and Breslow grade 4 disease were associated with mortality. The Kaplan-Meier curve revealed a shorter duration of recurrence time in the P53 mutation than P53 wild type. In the present study, P53 mutations in specific cases of cutaneous melanoma were identified. Notably, patients who were older and/or had a Breslow score of 4 exhibited an increased risk of mortality. These findings suggested the potential involvement of P53 mutations in cutaneous melanoma, highlighting the necessity for further investigations to improve understanding of their roles.